InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Monday, 05/23/2016 6:30:12 PM

Monday, May 23, 2016 6:30:12 PM

Post# of 240
ASCO - Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC) http://abstracts.asco.org/176/AbstView_176_170179.html

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC) http://abstracts.asco.org/176/AbstView_176_170710.html

Also CB-839 is going to be used in combo with Nivolumab in patients with clear cell renal cell carcinoma, melanoma and non-small cell lung cancer https://clinicaltrials.gov/ct2/show/NCT02771626?term=CB-839&rank=4
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CALA News